Annual EBITDA
-$157.19 M
-$69.38 M-79.01%
December 31, 2023
Summary
- As of February 12, 2025, SYRS annual EBITDA is -$157.19 million, with the most recent change of -$69.38 million (-79.01%) on December 31, 2023.
- During the last 3 years, SYRS annual EBITDA has fallen by -$77.98 million (-98.45%).
- SYRS annual EBITDA is now -1092.95% below its all-time high of -$13.18 million, reached on December 31, 2014.
Performance
SYRS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$4.76 M
+$16.86 M+77.98%
September 30, 2024
Summary
- As of February 12, 2025, SYRS quarterly EBITDA is -$4.76 million, with the most recent change of +$16.86 million (+77.98%) on September 30, 2024.
- Over the past year, SYRS quarterly EBITDA has increased by +$33.47 million (+87.55%).
- SYRS quarterly EBITDA is now -130.24% below its all-time high of -$2.07 million, reached on March 31, 2024.
Performance
SYRS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$91.14 M
+$33.47 M+26.86%
September 30, 2024
Summary
- As of February 12, 2025, SYRS TTM EBITDA is -$91.14 million, with the most recent change of +$33.47 million (+26.86%) on September 30, 2024.
- Over the past year, SYRS TTM EBITDA has increased by +$6.29 million (+6.46%).
- SYRS TTM EBITDA is now -1926.30% below its all-time high of -$4.50 million, reached on March 31, 2015.
Performance
SYRS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SYRS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -79.0% | +87.5% | +6.5% |
| 3 y3 years | -98.5% | +78.3% | -5.7% |
| 5 y5 years | -159.1% | +78.3% | -5.7% |
SYRS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -97.4% | at low | -130.2% | +92.4% | -14.4% | +42.0% |
| 5 y | 5-year | -116.4% | at low | -130.2% | +92.4% | -35.5% | +42.0% |
| alltime | all time | -1093.0% | at low | -130.2% | +92.4% | -1926.3% | +42.0% |
Syros Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.76 M(-78.0%) | -$91.14 M(-26.9%) |
| Jun 2024 | - | -$21.61 M(+945.7%) | -$124.61 M(-9.3%) |
| Mar 2024 | - | -$2.07 M(-96.7%) | -$137.33 M(-12.6%) |
| Dec 2023 | -$157.19 M(+79.0%) | -$62.70 M(+64.0%) | -$157.19 M(+61.3%) |
| Sep 2023 | - | -$38.23 M(+11.4%) | -$97.44 M(+11.0%) |
| Jun 2023 | - | -$34.33 M(+56.5%) | -$87.75 M(+1.7%) |
| Mar 2023 | - | -$21.93 M(+645.3%) | -$86.26 M(-1.8%) |
| Dec 2022 | -$87.81 M(+10.3%) | -$2.94 M(-89.7%) | -$87.81 M(-17.9%) |
| Sep 2022 | - | -$28.54 M(-13.1%) | -$106.92 M(+4.2%) |
| Jun 2022 | - | -$32.84 M(+39.8%) | -$102.66 M(+13.3%) |
| Mar 2022 | - | -$23.49 M(+6.5%) | -$90.59 M(+13.8%) |
| Dec 2021 | -$79.63 M(+0.5%) | -$22.05 M(-9.2%) | -$79.63 M(-7.8%) |
| Sep 2021 | - | -$24.28 M(+16.9%) | -$86.40 M(+7.5%) |
| Jun 2021 | - | -$20.77 M(+65.8%) | -$80.35 M(+6.4%) |
| Mar 2021 | - | -$12.53 M(-56.5%) | -$75.53 M(-4.6%) |
| Dec 2020 | -$79.21 M(+9.0%) | -$28.82 M(+58.1%) | -$79.21 M(+17.7%) |
| Sep 2020 | - | -$18.23 M(+14.3%) | -$67.29 M(-2.2%) |
| Jun 2020 | - | -$15.95 M(-1.6%) | -$68.81 M(-5.0%) |
| Mar 2020 | - | -$16.21 M(-4.1%) | -$72.41 M(-0.3%) |
| Dec 2019 | -$72.64 M | -$16.90 M(-14.4%) | -$72.64 M(+1.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$19.75 M(+1.0%) | -$71.90 M(+5.6%) |
| Jun 2019 | - | -$19.56 M(+19.0%) | -$68.07 M(+8.6%) |
| Mar 2019 | - | -$16.44 M(+1.8%) | -$62.68 M(+3.3%) |
| Dec 2018 | -$60.67 M(+14.1%) | -$16.16 M(+1.5%) | -$60.67 M(+1.7%) |
| Sep 2018 | - | -$15.91 M(+12.3%) | -$59.65 M(+3.9%) |
| Jun 2018 | - | -$14.17 M(-1.8%) | -$57.38 M(+1.8%) |
| Mar 2018 | - | -$14.43 M(-4.6%) | -$56.34 M(+6.0%) |
| Dec 2017 | -$53.16 M(+13.9%) | -$15.13 M(+10.9%) | -$53.16 M(+9.1%) |
| Sep 2017 | - | -$13.65 M(+3.9%) | -$48.74 M(-0.5%) |
| Jun 2017 | - | -$13.13 M(+16.7%) | -$48.99 M(+2.9%) |
| Mar 2017 | - | -$11.25 M(+5.1%) | -$47.61 M(+2.0%) |
| Dec 2016 | -$46.69 M(+59.8%) | -$10.71 M(-23.0%) | -$46.69 M(+0.5%) |
| Sep 2016 | - | -$13.90 M(+18.3%) | -$46.44 M(+13.8%) |
| Jun 2016 | - | -$11.75 M(+13.7%) | -$40.82 M(+16.4%) |
| Mar 2016 | - | -$10.33 M(-1.2%) | -$35.05 M(+20.0%) |
| Dec 2015 | -$29.22 M(+121.7%) | -$10.46 M(+26.4%) | -$29.22 M(+55.8%) |
| Sep 2015 | - | -$8.28 M(+38.3%) | -$18.76 M(+78.9%) |
| Jun 2015 | - | -$5.99 M(+33.1%) | -$10.48 M(+133.1%) |
| Mar 2015 | - | -$4.50 M | -$4.50 M |
| Dec 2014 | -$13.18 M | - | - |
FAQ
- What is Syros Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Syros Pharmaceuticals?
- What is Syros Pharmaceuticals annual EBITDA year-on-year change?
- What is Syros Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Syros Pharmaceuticals?
- What is Syros Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Syros Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Syros Pharmaceuticals?
- What is Syros Pharmaceuticals TTM EBITDA year-on-year change?
What is Syros Pharmaceuticals annual EBITDA?
The current annual EBITDA of SYRS is -$157.19 M
What is the all time high annual EBITDA for Syros Pharmaceuticals?
Syros Pharmaceuticals all-time high annual EBITDA is -$13.18 M
What is Syros Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, SYRS annual EBITDA has changed by -$69.38 M (-79.01%)
What is Syros Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of SYRS is -$4.76 M
What is the all time high quarterly EBITDA for Syros Pharmaceuticals?
Syros Pharmaceuticals all-time high quarterly EBITDA is -$2.07 M
What is Syros Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, SYRS quarterly EBITDA has changed by +$33.47 M (+87.55%)
What is Syros Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of SYRS is -$91.14 M
What is the all time high TTM EBITDA for Syros Pharmaceuticals?
Syros Pharmaceuticals all-time high TTM EBITDA is -$4.50 M
What is Syros Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, SYRS TTM EBITDA has changed by +$6.29 M (+6.46%)